Non-invasive analyser for lung cancer patients

Global cancer cases in both men and women in 2008 were estimated around 12.7 million and this number is expected to increase to 21 million. Lung cancer is one of the most common forms and figures suggest Europe and North America have the highest rates. Malnutrition is one of the most common symptoms of advanced lung cancer; timely identification and therapy can lead to improved patient outcomes. Prognostic biomarkers as established by the newly developed Maltron CScan could help select patients in cases where early discharge is safe. This would help redirect resources to patients in need. Maltron CScan is an easy and non-invasive technique to evaluate changes in cancer patients and is an independent prognostic indicator. Nutritional interventions targeted at improving biomarker results could potentially lead to an improved survival in patients.

Supplier: Maltron International Ltd.

Mail the supplier